{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T09:38:45Z","timestamp":1788514725644,"version":"build-2803163510"},"reference-count":51,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["K23AI141694"],"award-info":[{"award-number":["K23AI141694"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019212","name":"American Academy of Allergy, Asthma and Immunology Foundation","doi-asserted-by":"publisher","award":["U19 AI095219"],"award-info":[{"award-number":["U19 AI095219"]}],"id":[{"id":"10.13039\/100019212","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaci-inpractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.jaip.2021.12.030","type":"journal-article","created":{"date-parts":[[2022,1,6]],"date-time":"2022-01-06T11:32:00Z","timestamp":1641468720000},"page":"1462-1467","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"title":["Controversies in Allergy: Aspirin Desensitization or Biologics for Aspirin-Exacerbated Respiratory Disease\u2014How to Choose"],"prefix":"10.1016","volume":"10","author":[{"given":"Tanya M.","family":"Laidlaw","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek K.","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Whitney W.","family":"Stevens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew A.","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaip.2021.12.030_bib1","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.jaci.2014.08.020","article-title":"Prevalence of aspirin-exacerbated respiratory disease among asthmatic patients: a meta-analysis of the literature","volume":"135","author":"Rajan","year":"2015","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2021.12.030_bib2","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1056\/NEJMra1712125","article-title":"Aspirin-exacerbated respiratory disease","volume":"379","author":"White","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2021.12.030_bib3","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.jaci.2014.02.041","article-title":"Aspirin desensitization in patients with aspirin-induced and aspirin-tolerant asthma: a double-blind study","volume":"134","author":"Swierczynska-Krepa","year":"2014","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2021.12.030_bib4","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/S1081-1206(10)61803-0","article-title":"Early effects of aspirin desensitization treatment in asthmatic patients with aspirin-exacerbated respiratory disease","volume":"90","author":"Berges-Gimeno","year":"2003","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2021.12.030_bib5","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1177\/1945892418770260","article-title":"Long-term clinical outcomes of aspirin desensitization with continuous daily aspirin therapy in aspirin-exacerbated respiratory disease","volume":"32","author":"Walters","year":"2018","journal-title":"Am J Rhinol Allergy"},{"key":"10.1016\/j.jaip.2021.12.030_bib6","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1177\/0194599814545750","article-title":"Long-term sinonasal outcomes of aspirin desensitization in aspirin exacerbated respiratory disease","volume":"151","author":"Cho","year":"2014","journal-title":"Otolaryngol Head Neck Surg"},{"key":"10.1016\/j.jaip.2021.12.030_bib7","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s00405-012-2048-x","article-title":"Sinonasal outcome under aspirin desensitization following functional endoscopic sinus surgery in patients with aspirin triad","volume":"270","author":"Havel","year":"2013","journal-title":"Eur Arch Otorhinolaryngol"},{"key":"10.1016\/j.jaip.2021.12.030_bib8","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1002\/alr.22036","article-title":"Outcomes after complete endoscopic sinus surgery and aspirin desensitization in aspirin-exacerbated respiratory disease","volume":"8","author":"Adappa","year":"2018","journal-title":"Int Forum Allergy Rhinol"},{"key":"10.1016\/j.jaip.2021.12.030_bib9","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1002\/alr.21826","article-title":"Contemporary management of chronic rhinosinusitis with nasal polyposis in aspirin-exacerbated respiratory disease: an evidence-based review with recommendations","volume":"6","author":"Levy","year":"2016","journal-title":"Int Forum Allergy Rhinol"},{"key":"10.1016\/j.jaip.2021.12.030_bib10","doi-asserted-by":"crossref","first-page":"3565","DOI":"10.1016\/j.jaip.2020.06.063","article-title":"High discontinuation rates of peroral ASA treatment for CRSwNP: a real-world multicenter study of 171 N-ERD patients","volume":"8","author":"Laulajainen-Hongisto","year":"2020","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2021.12.030_bib11","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0247871","article-title":"Aspirin desensitization in NSAID-exacerbated respiratory disease and its outcomes in the clinical course of asthma: a systematic review of the literature and meta-analysis","volume":"16","author":"Eraso","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.jaip.2021.12.030_bib12","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/0091-6749(84)90361-0","article-title":"Aspirin-sensitive rhinosinusitis asthma: a double-blind crossover study of treatment with aspirin","volume":"73","author":"Stevenson","year":"1984","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2021.12.030_bib13","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/j.jaci.2020.10.043","volume":"147","author":"Stevens","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2021.12.030_bib14","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1016\/j.jaci.2021.09.009","article-title":"Comparative efficacy and safety of monoclonal antibodies and aspirin desensitization for chronic rhinosinusitis with nasal polyposis: a systematic review and network meta-analysis","volume":"149","author":"Oykhman","year":"2022","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2021.12.030_bib15","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/j.jaci.2020.08.025","article-title":"Impact of reported NSAID \"allergies\" on opioid use disorder in back pain","volume":"147","author":"Li","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2021.12.030_bib16","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jaci.2007.06.047","article-title":"An economic analysis of aspirin desensitization in aspirin-exacerbated respiratory disease","volume":"121","author":"Shaker","year":"2008","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2021.12.030_bib17","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1016\/j.jaip.2019.05.009","article-title":"Associations between inflammatory endotypes and clinical presentations in chronic rhinosinusitis","volume":"7","author":"Stevens","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2021.12.030_bib18","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1146\/annurev-pathol-052016-100401","article-title":"Immunopathogenesis of chronic rhinosinusitis and nasal polyposis","volume":"12","author":"Schleimer","year":"2017","journal-title":"Annu Rev Pathol"},{"key":"10.1016\/j.jaip.2021.12.030_bib19","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/j.jaci.2021.08.015","article-title":"Eicosanoid dysregulation and type 2 inflammation in AERD","volume":"148","author":"Mullol","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2021.12.030_bib20","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1016\/S0140-6736(19)31881-1","article-title":"Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials","volume":"394","author":"Bachert","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jaip.2021.12.030_bib21","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1111\/all.15067","article-title":"Efficacy and safety of dupilumab in patients with uncontrolled severe CRSwNP and a clinical diagnosis of NSAID-ERD: results from two randomized placebo-controlled phase 3 trials","volume":"77","author":"Mullol","year":"2022","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2021.12.030_bib22","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.jaci.2020.05.032","article-title":"Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials","volume":"146","author":"Gevaert","year":"2020","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2021.12.030_bib23","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/S2213-2600(21)00097-7","article-title":"Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"9","author":"Han","year":"2021","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaip.2021.12.030_bib24","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/j.jaci.2021.08.030","article-title":"Efficacy and safety of benralizumab in chronic rhinosinusitis with nasal polyps: a randomized, placebo-controlled trial","volume":"149","author":"Bachert","year":"2022","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2021.12.030_bib25","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1056\/NEJMoa1403290","article-title":"Mepolizumab treatment in patients with severe eosinophilic asthma","volume":"371","author":"Ortega","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2021.12.030_bib26","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1016\/S0140-6736(16)31324-1","article-title":"Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting beta2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial","volume":"388","author":"Bleecker","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jaip.2021.12.030_bib27","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1056\/NEJMoa1804092","article-title":"Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma","volume":"378","author":"Castro","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2021.12.030_bib28","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1016\/j.jaip.2019.02.037","article-title":"Sinus surgery improves lower respiratory tract reactivity during aspirin desensitization for AERD","volume":"7","author":"Huang","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2021.12.030_bib29","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1016\/j.jaip.2018.12.014","article-title":"Sinus surgery is associated with a decrease in aspirin-induced reaction severity in patients with aspirin exacerbated respiratory disease","volume":"7","author":"Jerschow","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2021.12.030_bib30","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.anai.2018.05.007","article-title":"Omalizumab can inhibit respiratory reaction during aspirin desensitization","volume":"121","author":"Lang","year":"2018","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2021.12.030_bib31","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.jaip.2016.12.013","article-title":"Aspirin tolerance in patients with nonsteroidal anti-inflammatory drug-exacerbated respiratory disease following treatment with omalizumab","volume":"5","author":"Phillips-Angles","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2021.12.030_bib32","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1164\/rccm.201906-1215OC","article-title":"Omalizumab for aspirin hypersensitivity and leukotriene overproduction in aspirin-exacerbated respiratory disease. A randomized controlled trial","volume":"201","author":"Hayashi","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaip.2021.12.030_bib33","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.jaci.2017.05.006","article-title":"Safety and outcomes of aspirin desensitization for aspirin-exacerbated respiratory disease: a single-center study","volume":"141","author":"Waldram","year":"2018","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2021.12.030_bib34","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1016\/j.jaip.2020.09.007","article-title":"Mepolizumab does not prevent all aspirin-induced reactions in patients with aspirin-exacerbated respiratory disease: a case series","volume":"9","author":"Martin","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2021.12.030_bib35","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.anai.2019.06.012","article-title":"Mepolizumab utility in successful aspirin desensitization in aspirin-exacerbated respiratory disease in a refractory case","volume":"123","author":"Mahdavinia","year":"2019","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2021.12.030_bib36","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.anai.2021.03.010","article-title":"Dupilumab increases aspirin tolerance in aspirin-exacerbated respiratory disease","volume":"126","author":"Mustafa","year":"2021","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2021.12.030_bib37","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.anai.2010.05.020","article-title":"Use of intranasal ketorolac and modified oral aspirin challenge for desensitization of aspirin-exacerbated respiratory disease","volume":"105","author":"Lee","year":"2010","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2021.12.030_bib38","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1016\/j.jaip.2018.10.032","article-title":"A\u00a01-day, 90-minute aspirin challenge and desensitization protocol in aspirin-exacerbated respiratory disease","volume":"7","author":"DeGregorio","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2021.12.030_bib39","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1016\/j.jaip.2018.08.004","article-title":"Comparable safety of 2 aspirin desensitization protocols for aspirin exacerbated respiratory disease","volume":"7","author":"Pelletier","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2021.12.030_bib40","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.jaci.2014.07.031","article-title":"Prostaglandin D(2): a dominant mediator of aspirin-exacerbated respiratory disease","volume":"135","author":"Cahill","year":"2015","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2021.12.030_bib41","doi-asserted-by":"crossref","first-page":"3170","DOI":"10.1016\/j.jaip.2020.06.061","article-title":"Leukotriene-associated rash in aspirin-exacerbated respiratory disease","volume":"8","author":"Laidlaw","year":"2020","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2021.12.030_bib42","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1002\/alr.22428","article-title":"Benefits and harms of aspirin desensitization for aspirin-exacerbated respiratory disease: a systematic review and meta-analysis","volume":"9","author":"Chu","year":"2019","journal-title":"Int Forum Allergy Rhinol"},{"key":"10.1016\/j.jaip.2021.12.030_bib43","doi-asserted-by":"crossref","first-page":"826","DOI":"10.7326\/M15-2112","article-title":"Bleeding risks with aspirin use for primary prevention in adults: a systematic review for the U.S. preventive services task force","volume":"164","author":"Whitlock","year":"2016","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jaip.2021.12.030_bib44","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1001\/jama.2018.20578","article-title":"Association of aspirin use for primary prevention with cardiovascular events and bleeding events: a systematic review and meta-analysis","volume":"321","author":"Zheng","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.jaip.2021.12.030_bib45","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S0140-6736(18)31133-4","article-title":"Effects of aspirin on risks of vascular events and cancer according to bodyweight and dose: analysis of individual patient data from randomised trials","volume":"392","author":"Rothwell","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.jaip.2021.12.030_bib46","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1709118","article-title":"Rivaroxaban with or without aspirin in stable cardiovascular disease","volume":"377","author":"Eikelboom","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2021.12.030_bib47","doi-asserted-by":"crossref","first-page":"3969","DOI":"10.1016\/j.jaip.2021.01.039","article-title":"Lower use of biologics for the treatment of asthma in publicly insured individuals","volume":"9","author":"Akenroye","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2021.12.030_bib48","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.jaip.2019.08.024","article-title":"Trends and disparities in asthma biologic use in the United States","volume":"8","author":"Inselman","year":"2020","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2021.12.030_bib49","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1002\/alr.22604","article-title":"Complete endoscopic sinus surgery followed by aspirin desensitization is associated with decreased overall corticosteroid use","volume":"10","author":"Bosso","year":"2020","journal-title":"Int Forum Allergy Rhinol"},{"key":"10.1016\/j.jaip.2021.12.030_bib50","doi-asserted-by":"crossref","first-page":"136","DOI":"10.2500\/aap.2021.42.210002","article-title":"Effectiveness of endoscopic sinus surgery and aspirin therapy in the management of aspirin-exacerbated respiratory disease","volume":"42","author":"Sweis","year":"2021","journal-title":"Allergy Asthma Proc"},{"key":"10.1016\/j.jaip.2021.12.030_bib51","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1002\/alr.22865","article-title":"Cost-effectiveness analysis comparing dupilumab and aspirin desensitization therapy for chronic rhinosinusitis with nasal polyposis in aspirin-exacerbated respiratory disease","volume":"11","author":"Yong","year":"2021","journal-title":"Int Forum Allergy Rhinol"}],"container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219822000022?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219822000022?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T05:32:58Z","timestamp":1761975178000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213219822000022"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":51,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["S2213219822000022"],"URL":"https:\/\/doi.org\/10.1016\/j.jaip.2021.12.030","relation":{},"ISSN":["2213-2198"],"issn-type":[{"value":"2213-2198","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Controversies in Allergy: Aspirin Desensitization or Biologics for Aspirin-Exacerbated Respiratory Disease\u2014How to Choose","name":"articletitle","label":"Article Title"},{"value":"The Journal of Allergy and Clinical Immunology: In Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaip.2021.12.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 American Academy of Allergy, Asthma & Immunology","name":"copyright","label":"Copyright"}]}}